Neoadjuvant anti–PD-1 prolgolimab monotherapy in resectable high-risk melanoma: Pathologic response and early event-free survival in a prospective single-arm phase II CRISTINA study.

9579 Background: In resectable high-risk melanoma, neoadjuvant anti–PD-1 aims to exceed the ~40% MPR benchmark; while combos may deepen response, they add tox, complexity, and cost. Recently reported data for prolgolimab+nurulimab (N = 205) showed pCR 38.5%, near-CR 4.4%, motivating evaluation of prolgolimab mono as a simpler potentially non-inferior approach. Methods: MelPRO-0322 (CRISTINA; NCT06299878) is a prospective single-arm study in resectable stage IIIB–IV melanoma: 3 neoadj doses of pr